Dulaglutide, a GLP-1 receptor agonist, reduced cognitive decline, neuronal damage, and brain inflammation in vascular dementia rats by suppressing cell death and activating the PI3K/Akt/mTOR neuroprotective signaling pathway.
Cognitive decline significantly reducedDulaglutide improved Morris water maze performance while protecting hippocampal neurons and activating the PI3K/Akt/mTOR neuroprotective pathway in vascular dementia rats
What the researchers found
In vascular dementia rats, dulaglutide treatment produced multiple neuroprotective effects:
- Cognitive improvement: Morris water maze testing showed significantly reduced cognitive decline
- Neuroprotection: Neuronal damage in the hippocampus was significantly alleviated
- Reduced gliosis: Microglial and astrocyte proliferation (inflammation markers) were decreased
- Anti-apoptotic effects: BCL2/BAX ratio and cleaved caspase-3 indicated reduced cell death
- Autophagy regulation: P62, LC3B, and Beclin-1 markers showed normalized autophagy
- Mechanism: PI3K/Akt/mTOR signaling pathway was activated, with the mTOR repressor Deptor downregulated
RNA sequencing confirmed that mTOR pathway genes were significantly enriched among differentially expressed genes in the dulaglutide group.
Why it matters
Vascular dementia is the second most common form of dementia after Alzheimer's disease and currently has no approved disease-modifying treatments. The finding that dulaglutide — an already FDA-approved diabetes drug — can protect against vascular dementia in animal models is significant because drug repurposing can dramatically shorten the path to clinical use. This adds to mounting evidence that GLP-1 drugs have neuroprotective effects beyond their metabolic actions, with potential applications across multiple forms of dementia.
How the study worked
Vascular dementia was induced in Sprague-Dawley rats by bilateral carotid artery occlusion. Cognitive function was assessed using the Morris water maze (learning/memory) and open-field test (anxiety behavior). Brain tissue was analyzed using HE staining and immunofluorescence for neuronal damage and glial cell proliferation. Western blotting measured apoptosis and autophagy markers plus PI3K/Akt/mTOR pathway activation. RNA sequencing with KEGG pathway analysis identified differentially expressed genes and enriched pathways.
What this study cannot tell us
This is a preclinical rat study using an acute surgical model of vascular dementia, which may not fully replicate the chronic, progressive nature of human vascular dementia. Only one dose of dulaglutide was tested, so the optimal dosing regimen is unknown. The bilateral carotid artery occlusion model is severe and does not represent the typical gradual small vessel disease that causes most human vascular dementia. Long-term safety and efficacy of brain-targeted GLP-1RA treatment were not assessed.
How to read the evidence
This is a preclinical animal study with comprehensive mechanistic analysis including behavioral testing, histology, protein analysis, and RNA sequencing. While the multi-level evidence is compelling for a preclinical study, the findings have not been validated in humans and the surgical model has limitations for translating to human vascular dementia.
When this study was published
Published in 2023, this is a recent study contributing to the active investigation of GLP-1RA neuroprotection, a field with several ongoing clinical trials in related neurodegenerative conditions.
The bigger picture
This study adds vascular dementia to the growing list of neurological conditions where GLP-1 receptor agonists show neuroprotective potential — joining Alzheimer's disease and Parkinson's disease. The mechanistic detail provided (PI3K/Akt/mTOR pathway, RNA sequencing) strengthens the scientific case for GLP-1RA neuroprotection beyond simple correlation. As clinical trials of GLP-1RAs for neurodegenerative diseases advance, preclinical studies like this help identify the molecular pathways being targeted.
Questions still open
- Would dulaglutide show similar neuroprotective effects in human vascular dementia patients?
- Is the PI3K/Akt/mTOR pathway the primary mechanism for all GLP-1RA neuroprotective effects or specific to vascular dementia?
- Could dulaglutide be more effective for vascular dementia than for Alzheimer's disease given the vascular mechanism?
Common questions
What is vascular dementia and how is it different from Alzheimer's?
Could people with diabetes taking dulaglutide already be getting brain protection?
Read the original research
Dulaglutide Improves Gliosis and Suppresses Apoptosis/Autophagy Through the PI3K/Akt/mTOR Signaling Pathway in Vascular Dementia Rats.
Neurochemical research, 48(5), 1561-1579
Citation
Guan, Tianyuan; Xiao, Yining; Xie, Xiaohua; Meng, Nan; Qi, Qianqian; Xu, Jing; Jiang, Xin; Zhang, Zhe; Teng, Zhenjie; Lv, Peiyuan. (2023). Dulaglutide Improves Gliosis and Suppresses Apoptosis/Autophagy Through the PI3K/Akt/mTOR Signaling Pathway in Vascular Dementia Rats.. Neurochemical research, 48(5), 1561-1579. https://doi.org/10.1007/s11064-022-03853-0